Sign In
Buy CDNA
$38.37
-1.36 (-3.42%)
At Close: Jul 20, 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of c
CareDx to Report Second Quarter 2025 Financial Results
07:05am, Wednesday, 23'rd Jul 2025
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healt
CareDx (CDNA) Surges 7.0%: Is This an Indication of Further Gains?
08:10am, Tuesday, 22'nd Jul 2025
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road
CareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant Rejection
08:00am, Friday, 18'th Jul 2025
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of cl
CareDx: The Transplant Diagnostics Leader, But Challenges Will Increase On The Road Ahead
07:23am, Saturday, 14'th Jun 2025
CareDx has a unique, comprehensive organ transplant diagnostics portfolio and maintains strong revenue growth, but faces intensifying competition and regulatory risks. Recent legal resolutions and ope
CareDx Announces Repurchase of 5% of Outstanding Shares
04:30pm, Tuesday, 03'rd Jun 2025
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of c
Johnson Fistel has Commenced an Investigation on Behalf of CareDx, Inc. Shareholders
09:27am, Thursday, 22'nd May 2025
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of CareDx, Inc. (NASDAQ: CDNA) for
Johnson Fistel has Commenced an Investigation on Behalf of CareDx, Inc. Shareholders
08:48pm, Wednesday, 21'st May 2025
SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of CareDx, Inc. (N
CareDx to Participate in Upcoming Investor Conferences
04:01pm, Tuesday, 13'th May 2025
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of cl
CareDx, Inc (CDNA) Q1 2025 Earnings Call Transcript
08:39pm, Wednesday, 30'th Apr 2025
CareDx, Inc (NASDAQ:CDNA ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Caroline Corner - Investor Relations John Hanna - President & Chief Executive Officer Robert
CareDx (CDNA) Tops Q1 Earnings Estimates
06:50pm, Wednesday, 30'th Apr 2025
CareDx (CDNA) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.03 per share a year ago.
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of cl
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Monday, 21'st Apr 2025
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ (“CareDx” or the “Company”)— a leading precision medicine company focused on the discovery, devel
CareDx to Report First Quarter 2025 Financial Results
07:05am, Tuesday, 08'th Apr 2025
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healt
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues
